



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



**Australian Securities Exchange Limited  
Companies Announcements Office  
SYDNEY**

**25 October 2012**

### **Director's Resignation**

Bioxyne Limited (ASX:BXN) today advises of the resignation from the Board of Dr Doug Wilson, effective Friday October 26<sup>th</sup> 2012.

The Board would like to thank Dr Wilson for his contributions to the Company, and in particular acknowledge his inputs and involvement in the clinical study HI-H005.

The Company wishes Dr Wilson well in his other business developments.

For Further information please contact:

David Radford  
Chief Executive Officer  
Tel: +61 (0) 407-218-922

Tim Allerton or Andrew Geddes  
CityPR  
(02) 9267

### **About Bioxyne**

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company's lead therapy, HI-164OV is based on the Company's proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit [www.bioxyne.com](http://www.bioxyne.com)

## **COPD**

Chronic Obstructive Pulmonary Disease (COPD) is a disease largely caused by smoking but with a rising number of new cases caused by pollution in developing countries like China and India. The global demand for COPD treatments is growing rapidly with an analysis by the Australian Lung Foundation in 2008 indicating the wide economic cost of to the Australian economy in 2010 was estimated to be \$9 billion in direct and indirect costs, with \$1 billion incurred in direct health system expenditure. There are currently no effective treatments for COPD and 25 per cent of COPD patients admitted to hospital die within one year. Reducing hospital admissions is crucial and preventing exacerbations is the main choice of therapy. More than 15 per cent of new patients have never smoked and Industrial pollution is viewed as a major risk factor in the onset of COPD. It is estimated COPD will be third leading cause of mortality in the next decade, behind heart failure and cancer.